Product Comparison


 
Seqirus USA Inc 33332042110
Seqirus USA Inc 33332022120
Medimmune 66019030810
Seqirus USA Inc 70461042110
McKesson # 1183078 1183072 1182039 1183068
Description Afluria® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Afluria® Quadrivalent 2021 - 2022 Pediatric Flu Vaccine 30 mcg / 0.25 mL Indicated For People 6 Months to 35 Months of Age Prefilled Syringe 0.25 mL FluMist® Quadrivalent 2021 - 2022 Flu Vaccine 10E6.5 - 7.5 FFU Indicated For People 2 to 49 Years of Age Intranasal Sprayer 0.2 mL Flucelvax® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 6 Months of Age and Above Multiple Dose Vial 5 mL
Manufacturer # 33332042110333320221206601903081070461042110
Brand Afluria® Quadrivalent 2021 - 2022Afluria® Quadrivalent 2021 - 2022 PediatricFluMist® Quadrivalent 2021 - 2022Flucelvax® Quadrivalent 2021 - 2022
Manufacturer Seqirus USA IncSeqirus USA IncMedimmuneSeqirus USA Inc
Invoice AFLURIA 2021, QUAD MDV 5ML (10DOSE/VL)AFLURIA 2021, QUAD SYR PED 0.25ML (10DOSE/BX)FLUMIST QUAD 2021, SPR (10DOSE/BX)FLUCELVAX 2021, QUAD MDV 5ML (10DOSE/VL)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 1586551
Container Type Multiple Dose VialPrefilled SyringeIntranasal SprayerMultiple Dose Vial
Country of Origin AustraliaAustraliaUnited StatesUnited States
Dosage Form InjectionInjectionSprayInjection
Generic Drug Code 4958349796
NDC Number 33332042110333320221206601903081070461042110
Strength 60 mcg / 0.5 mL30 mcg / 0.25 mL10E6.5 - 7.5 FFU60 mcg / 0.5 mL
Type IntramuscularIntramuscularIntranasalIntramuscular
User Indicated For People 6 Months of Age and AboveIndicated For People 6 Months to 35 Months of AgeIndicated For People 2 to 49 Years of AgeIndicated For People 6 Months of Age and Above
Volume 5 mL0.25 mL0.2 mL5 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu Vaccine
Product Dating McKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 days
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
UNSPSC Code 51201608512016085120160851201608
Features and Benefits
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2021 - 2022 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2020 - 2021 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • AFLURIA® QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • 5 mL multi-dose vial ( for persons 6 months of age and older).
  • AFLURIA QUADRIVALENT is a sterile suspension for intramuscular injection
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2021 - 2022 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2020 - 2021 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • FluMist®Quadrivalent (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • FluMist®Quadrivalent is for intranasal administration only
  • FluMist Quadrivalent contains 4 influenza virus strains that are weakened (A(H1N1), A(H3N2), B Yamagata lineage, and B Victoria lineage)
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX QUADRIVALENT is approved for use in persons 6 Months of age and older
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2021 - 2022 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)